Following positive phase 2 results and orphan drug designation, biodexa's fap drug receives fda fast track status

Cardiff, uk / access newswire / february 12, 2025 / biodexa pharmaceuticals plc. (nasdaq:bdrx), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, received fast track status from the u.s. food and drug administration for erapa, a proprietary encapsulated form of rapamycin being developed for the treatment of familial adenomatous polyposis (fap).
BDRX Ratings Summary
BDRX Quant Ranking